Concise Prescribing Info. Dosage Details. Hepatic Impairment. Severe: Contraindicated.
|Published (Last):||23 July 2012|
|PDF File Size:||19.37 Mb|
|ePub File Size:||3.65 Mb|
|Price:||Free* [*Free Regsitration Required]|
Concise Prescribing Info. Dosage Details. Hepatic Impairment. Severe: Contraindicated. Dilute in NaCl 0. Special Precautions. Disease states and other circumstances in which there is an increased risk of haemorrhage e. Critically ill patients. Moderate hepatic impairment. Pregnancy and lactation. Adverse Reactions. Haemorrhagic effects e. GI bleeding, haematuria, hemoptysis , hypotension, fever, dyspnoea, diarrhoea, sepsis, nausea, cardiac arrest, ventricular tachycardia, pain, UTI, vomiting, infection, pneumonia, AF, cough, abnormal renal function, abdominal pain, cerebrovascular disorder, chest and back pain, headache, MI, bradycardia.
Management: Symptomatic and supportive treatment. Drug Interactions. Description: Argatroban is a synthetic direct thrombin inhibitor which reversibly binds to the active thrombin site of free and clot-associated thrombin.
It exerts its anticoagulant effects by inhibiting thrombin-catalysed or -induced reactions, e. Onset: Immediate. Pharmacokinetics: Absorption: Time to peak plasma concentration: Steady-state: hr. Distribution: Distributed mainly in the extra-cellular fluid. Terminal elimination half-life: min. Chemical Structure. Do not freeze. Protect from light.
MIMS Class. ATC Classification. B01AE03 - argatroban ; Belongs to the class of direct thrombin inhibitors. Used in the treatment of thrombosis. Disclaimer: This information is independently developed by MIMS based on Argatroban from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries.
Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. All rights reserved. Powered by MIMS. Exclusive offer for doctors. Sign up for free. Already a member? Sign in. Reconstitution Dilute in NaCl 0.
Contraindications Active major bleeding. Severe hepatic impairment. Special Precautions Disease states and other circumstances in which there is an increased risk of haemorrhage e.
Adverse Reactions Haemorrhagic effects e. Action Description: Argatroban is a synthetic direct thrombin inhibitor which reversibly binds to the active thrombin site of free and clot-associated thrombin.
We'd like to understand how you use our websites in order to improve them. Register your interest. Antithrombotic and antiplatelet therapies are the cornerstones of management of cardiovascular disorders today. Due to the safety and efficacy limitations of the classic antithrombotic, unfractionated heparin, considerable effort has been directed at developing novel anticoagulants. Direct thrombin inhibitors as a class of drugs offer inhibition of clot-bound as well as fluid-phase thrombin and a more predictable anticoagulant response. Specifically, argatroban, a synthetic small molecule direct thrombin inhibitor, selectively inhibits the catalytic site of thrombin in a reversible manner. Overall, argatroban's short half-life, ease of monitoring with an activated partial thromboplastin time, and safety in renal failure patients make this drug the preferable mode therapy for prevention of thrombosis in heparin-induced thrombocytopenia.